Yi Dang

机构：Chinese Academy of Sciences, Institute of Tibetan Plateau Research · ORCID：0000-0001-9704-6053

发表论文 67 篇 · 总被引 619 次 · h-index 16

代表论文

• Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure (2022 · Frontiers in Pharmacology · 被引 30)
• Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial (2024 · EClinicalMedicine · 被引 25)
• The HALP score predicts no-reflow phenomenon and long-term prognosis in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention (2024 · Coronary Artery Disease · 被引 19)
• Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation (2024 · Cardiovascular Diabetology · 被引 17)
• Association between total ischemic time and in-hospital mortality after emergency PCI in patients with acute ST-segment elevation myocardial infarction: a retrospective study (2022 · BMC Cardiovascular Disorders · 被引 12)
• Nomogram for Predicting In-Hospital Mortality in Patients with Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock after Primary Percutaneous Coronary Intervention (2022 · Journal of Interventional Cardiology · 被引 10)